TY - JOUR
TI - Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
AU - Zarogoulidis, P.
AU - Chinelis, P.
AU - Athanasiadou, A.
AU - Tsiouda, T.
AU - Trakada, G.
AU - Kallianos, A.
AU - Veletza, L.
AU - Hatzibougias, D.
AU - Mihalopoulou, E.
AU - Goupou, E.
AU - Kosmidis, C.
AU - Sardeli, C.
AU - Huang, H.
AU - Hohenforst-Schmidt, W.
JO - Respiratory Medicine Case Reports
PY - 2017
VL - 22
TODO - null
SP - 101-105
PB - W.B. Saunders Ltd
SN - 2213-0071
TODO - 10.1016/j.rmcr.2017.07.004
TODO - anaplastic lymphoma kinase;  carboplatin;  epidermal growth factor receptor;  gemcitabine;  methylprednisolone;  nivolumab;  paclitaxel;  pembrolizumab;  programmed death 1 ligand 1;  taxane derivative;  zoledronic acid, abdominal organ rupture;  adult;  adverse drug reaction;  aged;  Article;  cancer immunotherapy;  cancer patient;  cancer therapy;  case report;  follow up;  gene mutation;  human;  lung adenocarcinoma;  male;  multiple cycle treatment;  neutropenia;  non small cell lung cancer;  pharmacogenomics;  priority journal;  squamous cell lung carcinoma
TODO - In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients. © 2017 The Authors
ER -